FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2315704032> ?p ?o ?g. }

• W2315704032 endingPage "287" @default.
• W2315704032 startingPage "280" @default.
• W2315704032 abstract "Background: The use of combination antiretroviral therapy (cART) has significantly decreased the morbidity and mortality associated with human immunodeficiency virus (HIV) infection. Lipid disorders, including lipodystrophy, hypertriglyceridemia, and hypercholesterolemia, remain the most commonly reported metabolic disorders among those treated with long-term cART. Mounting evidence suggests an association between drug abuse and poor glycemic control and diabetes complications. Substance related disorders (SRD) may increase the risk of metabolic syndrome. Materials and Methods: The aim of this retrospective cohort study was to examine the relationship between SRD, cART, and lipid-lowering agent use in an HIV infected population. Patients received efavirenz or protease inhibitor-based cART for at least 6 months. Prescription information was retrieved from the medical records. The primary outcome was the use of lipid-lowering agents including statins, fibrates and fish oil. The impact of SRD and cART was assessed on the lipidlowering agent use. Results: A total of 276 subjects with HIV infection were included, 90 (33%) received lipid-lowering agents, and 31 (34%) had SRD. Smoking was prevalent among subjects with SRD (84 vs 15%, p<0.001). Statins were the mainstay for the management of dyslipidemia (66%), followed by the fibrates (24%), omega-3 fatty acids (5%), nicotinic acid (3%) and the cholesterol absorption inhibitors (3%). Use of statins or fibrates was significantly higher among subjects without SRD than those with (40 vs 23%, p=0.005). The type of cART, including efavirenz and protease inhibitors, appeared to have no significant impact on the use pattern of lipid-lowering agents. Lopinavir/ritonavir (lopinavir/r) was mostly prescribed for subjects with SRD (25 vs 8%, p=0.02). Conclusion: Among HIV-infected patients, statins remain the mainstay for the management of dyslipidemia in routine clinical care, followed by fibrates. A significant high risk of metabolic disorders among patients with SRD is implicated by heavy tobacco use and prevalent lopinavir/r-based treatment. Significantly low rate of lipid-lowering agent use in this population underscores the importance of lipid disorder scrutiny and cART treatment optimization for HIV-infected patients with SRD. Keywords: Substance-related disorders, HIV, metabolic disorder, dyslipidemia, lipid-lowering therapy, statins, fibrates." @default.
• W2315704032 created "2016-06-24" @default.
• W2315704032 creator A5001380703 @default.
• W2315704032 creator A5035888524 @default.
• W2315704032 creator A5037196439 @default.
• W2315704032 creator A5055908944 @default.
• W2315704032 creator A5063986557 @default.
• W2315704032 creator A5066252006 @default.
• W2315704032 creator A5067890214 @default.
• W2315704032 creator A5070552330 @default.
• W2315704032 creator A5074673860 @default.
• W2315704032 creator A5075585167 @default.
• W2315704032 creator A5084232309 @default.
• W2315704032 date "2016-03-16" @default.
• W2315704032 modified "2023-09-27" @default.
• W2315704032 title "Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders" @default.
• W2315704032 cites W1767400858 @default.
• W2315704032 cites W1966331992 @default.
• W2315704032 cites W1968420582 @default.
• W2315704032 cites W1968607641 @default.
• W2315704032 cites W1968940004 @default.
• W2315704032 cites W1969337281 @default.
• W2315704032 cites W197130036 @default.
• W2315704032 cites W1977267806 @default.
• W2315704032 cites W1978444406 @default.
• W2315704032 cites W1984538952 @default.
• W2315704032 cites W1984717040 @default.
• W2315704032 cites W1993508860 @default.
• W2315704032 cites W1997431249 @default.
• W2315704032 cites W2000359142 @default.
• W2315704032 cites W2001555648 @default.
• W2315704032 cites W2002615726 @default.
• W2315704032 cites W2003213783 @default.
• W2315704032 cites W2003421870 @default.
• W2315704032 cites W2006597723 @default.
• W2315704032 cites W2011914025 @default.
• W2315704032 cites W2015127450 @default.
• W2315704032 cites W2031378391 @default.
• W2315704032 cites W2042402060 @default.
• W2315704032 cites W2042972934 @default.
• W2315704032 cites W2049863380 @default.
• W2315704032 cites W2057674977 @default.
• W2315704032 cites W2062715454 @default.
• W2315704032 cites W2074096139 @default.
• W2315704032 cites W2088643134 @default.
• W2315704032 cites W2090600505 @default.
• W2315704032 cites W2098751206 @default.
• W2315704032 cites W2110916536 @default.
• W2315704032 cites W2124546057 @default.
• W2315704032 cites W2133107560 @default.
• W2315704032 cites W2136162563 @default.
• W2315704032 cites W2140150768 @default.
• W2315704032 cites W2142481435 @default.
• W2315704032 cites W2150961630 @default.
• W2315704032 cites W2151838240 @default.
• W2315704032 cites W2152506392 @default.
• W2315704032 cites W2156188065 @default.
• W2315704032 cites W2164779028 @default.
• W2315704032 cites W2317619427 @default.
• W2315704032 cites W2324473093 @default.
• W2315704032 cites W2331831814 @default.
• W2315704032 cites W2396336957 @default.
• W2315704032 cites W2408836370 @default.
• W2315704032 doi "https://doi.org/10.2174/1570161114666160106151652" @default.
• W2315704032 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4879810" @default.
• W2315704032 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26733388" @default.
• W2315704032 hasPublicationYear "2016" @default.
• W2315704032 type Work @default.
• W2315704032 sameAs 2315704032 @default.
• W2315704032 citedByCount "8" @default.
• W2315704032 countsByYear W23157040322017 @default.
• W2315704032 countsByYear W23157040322019 @default.
• W2315704032 countsByYear W23157040322020 @default.
• W2315704032 countsByYear W23157040322022 @default.
• W2315704032 crossrefType "journal-article" @default.
• W2315704032 hasAuthorship W2315704032A5001380703 @default.
• W2315704032 hasAuthorship W2315704032A5035888524 @default.
• W2315704032 hasAuthorship W2315704032A5037196439 @default.
• W2315704032 hasAuthorship W2315704032A5055908944 @default.
• W2315704032 hasAuthorship W2315704032A5063986557 @default.
• W2315704032 hasAuthorship W2315704032A5066252006 @default.
• W2315704032 hasAuthorship W2315704032A5067890214 @default.
• W2315704032 hasAuthorship W2315704032A5070552330 @default.
• W2315704032 hasAuthorship W2315704032A5074673860 @default.
• W2315704032 hasAuthorship W2315704032A5075585167 @default.
• W2315704032 hasAuthorship W2315704032A5084232309 @default.
• W2315704032 hasBestOaLocation W23157040322 @default.
• W2315704032 hasConcept C126322002 @default.
• W2315704032 hasConcept C134018914 @default.
• W2315704032 hasConcept C142462285 @default.
• W2315704032 hasConcept C203014093 @default.
• W2315704032 hasConcept C2776919658 @default.
• W2315704032 hasConcept C2778096610 @default.
• W2315704032 hasConcept C2778163477 @default.
• W2315704032 hasConcept C2778913445 @default.
• W2315704032 hasConcept C2779134260 @default.
• W2315704032 hasConcept C2779298103 @default.
• W2315704032 hasConcept C2780941825 @default.

• next